COMPANY
Viridian Therapeutics, Inc.
FDA-approved therapeutic company Clinical Phase 3
Viridian Therapeutics uses antibody discovery and engineering to build a pipeline of investigational therapeutic candidates, including a thyroid eye disease program. From company website Source · checked 2026-10-19
Sources for this description (1)
- Viridian Therapeutics uses antibody discovery and engineering to build a pipeline of investigational therapeutic candidates, including a thyroid eye disease program.
- “Leveraging our team’s expertise in antibody discovery and engineering, we have created a robust pipeline of differentiated investigational therapeutic candidates for well-validated targets.” https://www.viridiantherapeutics.com/about/ (2026-10-19)
- “Our thyroid eye disease program is an example of our drug development strategy in action, aiming to improve upon the standard-of-care and currently available treatment options within commercially established disease areas, with the ultimate goal of improving patients’ lives.” https://www.viridiantherapeutics.com/about/ (2026-10-19)
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| [TEMPLATE] General | Waltham, MA - US | Sep 24, 2026 | Oct 16, 2026 |
| [TEMPLATE] General (UK) | Remote - UK | Sep 24, 2026 | Oct 16, 2026 |
Timeline
- Trial start Phase 4: An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab source ↗
- FDA FDA New drug/biologic (novel): LUMVOA (veligrotug-vvze) — BLA761530, Jun 26, 2026. Applicant at approval: Viridian Therapeutics, Inc. source ↗
- Trial start Phase 3: A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) source ↗
- Trial start Phase 3: A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) source ↗
- Trial start Phase 3: An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED) source ↗
- Trial start Phase 3: An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) source ↗
- Trial start Phase 3: A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) source ↗
- Trial start Phase 3: An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301 source ↗
- Trial start Phase 3: An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) source ↗
- Trial start Phase 3: A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED) source ↗
Upcoming milestones
- 2027-04 (ESTIMATED) · Phase 4 · An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab · NCT07832136
Clinical trials (lead sponsor) 9
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07832136 | An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab | Phase 4 | Not yet recruiting | 2026-09 | 2027-04 (estimated) |
| NCT06625398 | An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED) | Phase 3 | Active, not recruiting | Aug 27, 2024 | Mar 4, 2026 (actual) |
| NCT06625411 | An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) | Phase 3 | Active, not recruiting | Aug 27, 2024 | Feb 12, 2026 (actual) |
| NCT06179875 | An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301 | Phase 3 | Completed | Jan 31, 2024 | Apr 25, 2025 (actual) |
| NCT06021054 | An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) | Phase 3 | Completed | Nov 1, 2023 | Nov 4, 2024 (actual) |
| NCT05176639 | A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED) | Phase 3 | Completed | Nov 16, 2022 | Jul 15, 2024 (actual) |
| NCT06384547 | A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) | Phase 3 | Completed | May 23, 2024 | May 1, 2025 (actual) |
| NCT07155668 | A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) | Phase 3 | Completed | Jul 1, 2025 | May 28, 2026 (actual) |
| NCT06812325 | A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) | Phase 3 | Active, not recruiting | Feb 3, 2025 | Apr 22, 2026 (actual) |
FDA records (last 2 years)
- FDA New drug/biologic (novel): LUMVOA (veligrotug-vvze) — BLA761530, Jun 26, 2026. Applicant at approval: Viridian Therapeutics, Inc. source ↗
Open jobs 2
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| [TEMPLATE] General | Waltham, MA - US | Sep 24, 2026 | Oct 16, 2026 | Not stated |
| [TEMPLATE] General (UK) | Remote - UK | Sep 24, 2026 | Oct 16, 2026 | Not stated |
Connect
See your connections at Viridian Therapeutics on LinkedIn (search by name, results not checked)